Full Text View
Tabular View
No Study Results Posted
Related Studies
Compare the Efficacy and Safety of 48-Week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection
This study is ongoing, but not recruiting participants.
Study NCT00362635.   Last updated on May 16, 2008.
Information provided by Bukwang Pharmaceutical
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis B
Additional conditions recognized in this trial
Hepatitis
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Virus Diseases
Interventions listed in this trial
Clevudine
Additional drug interventions recognized in this trial
2'-fluoro-5-methylarabinosyluracil
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Bukwang Pharmaceutical


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services